Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Schiffmann

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
Coronary Artery Disease|December 23, 2016
Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery diseaseAnupama Vasudevan, Teodoro Bottiglieri, Kristen M Tecson, et al.
Journal of Inherited Metabolic Disease|August 28, 2015
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry miceJin-Song Shen, Andreas Busch, Taniqua S Day, et al.
Medicine|March 13, 2002
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical courseMary H Branton, Raphael Schiffmann, Sharda G Sabnis, et al.
Journal of Inherited Metabolic Disease|November 8, 2017
Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expressionXing-Li Meng, Erland Arning, Mary Wight-Carter, et al.
Frontiers in Neurology|January 31, 2018
Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological FindingsTatiana Bremova-Ertl, Raphael Schiffmann, Marc C Patterson, et al.
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Neurology. Genetics|August 18, 2020
D-DEMØ, a distinct phenotype caused by <i>ATP1A3</i> mutationsLyndsey Prange, Milton Pratt, Kristin Herman, et al.
Clinical Pharmacology in Drug Development|April 20, 2021
Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in MiceYi Shuan Wu, Richie Khanna, Virginia Schmith, et al.
Molecular Genetics and Metabolism|November 22, 2016
Roscoe Owen Brady, MD: Remembrances of co-investigators and colleaguesRobert J Desnick, Norman W Barton, Scott Furbish, et al.
Brain : a Journal of Neurology|October 18, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trialRaphael Schiffmann, Timothy M Cox, Jean-François Dedieu, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
Coronary Artery Disease|December 23, 2016
Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery diseaseAnupama Vasudevan, Teodoro Bottiglieri, Kristen M Tecson, et al.
Journal of Inherited Metabolic Disease|August 28, 2015
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry miceJin-Song Shen, Andreas Busch, Taniqua S Day, et al.
Medicine|March 13, 2002
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical courseMary H Branton, Raphael Schiffmann, Sharda G Sabnis, et al.
Journal of Inherited Metabolic Disease|November 8, 2017
Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expressionXing-Li Meng, Erland Arning, Mary Wight-Carter, et al.
Frontiers in Neurology|January 31, 2018
Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological FindingsTatiana Bremova-Ertl, Raphael Schiffmann, Marc C Patterson, et al.
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Neurology. Genetics|August 18, 2020
D-DEMØ, a distinct phenotype caused by <i>ATP1A3</i> mutationsLyndsey Prange, Milton Pratt, Kristin Herman, et al.
Clinical Pharmacology in Drug Development|April 20, 2021
Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in MiceYi Shuan Wu, Richie Khanna, Virginia Schmith, et al.
Molecular Genetics and Metabolism|November 22, 2016
Roscoe Owen Brady, MD: Remembrances of co-investigators and colleaguesRobert J Desnick, Norman W Barton, Scott Furbish, et al.
Brain : a Journal of Neurology|October 18, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trialRaphael Schiffmann, Timothy M Cox, Jean-François Dedieu, et al.
Pageof 23